- Muscle loss is disproportionate. The median proportion of weight loss attributable to muscle-related indices was ~35% across incretin groups, exceeding the established ~25% benchmark (for FFM/lean soft tissue) in 68% of studies.
- Newer agents lose more muscle in absolute terms. Semaglutide and tirzepatide produced greater total weight loss — and correspondingly greater absolute muscle loss — than older agents like liraglutide or dulaglutide, though head-to-head comparisons were absent.
- This isn't unique to GLP-1 drugs. Half of lifestyle/placebo comparator groups that lost weight also exceeded muscle-loss benchmarks, suggesting disproportionate lean tissue loss is a broader feature of intentional weight loss, not just a drug-specific effect.
- Older adults are an unaddressed gap. Only 4 studies included participants with a mean age ≥60, and none focused on adults ≥65 — the population most vulnerable to sarcopenic obesity and functional decline from muscle loss.
- Functional outcomes are missing entirely. Not a single included study measured objective physical performance (strength, mobility, endurance), making it impossible to determine whether observed muscle losses translate into real-world functional impairment — a critical evidence gap.
Incretin Trials Often Exceed Muscle-Loss Benchmarks
Conexiant
April 17, 2026
